Personalis, Inc. $PSNL Shares Purchased by AIGH Capital Management LLC

AIGH Capital Management LLC raised its holdings in Personalis, Inc. (NASDAQ:PSNL) by 4.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,892,101 shares of the company’s stock after purchasing an additional 168,143 shares during the quarter. Personalis makes up about 7.2% of AIGH Capital Management LLC’s investment portfolio, making the stock its 3rd largest position. AIGH Capital Management LLC owned approximately 4.39% of Personalis worth $25,376,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Royal Bank of Canada grew its stake in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares during the last quarter. Howland Capital Management LLC boosted its position in Personalis by 0.9% in the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after buying an additional 2,500 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Personalis in the 2nd quarter valued at $30,000. Ameritas Investment Partners Inc. bought a new stake in shares of Personalis during the second quarter worth $34,000. Finally, BNP Paribas Financial Markets raised its position in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Wall Street Analysts Forecast Growth

PSNL has been the topic of several recent research reports. Lake Street Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Personalis in a report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Wednesday, October 8th. Needham & Company LLC boosted their price target on shares of Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Morgan Stanley raised their price objective on shares of Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a research note on Monday, December 1st. Finally, Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.57.

Personalis Price Performance

Personalis stock opened at $10.17 on Friday. The firm has a market capitalization of $903.10 million, a price-to-earnings ratio of -11.56 and a beta of 1.96. The company’s 50 day simple moving average is $9.06 and its 200 day simple moving average is $7.46. Personalis, Inc. has a fifty-two week low of $2.83 and a fifty-two week high of $11.50.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The company had revenue of $14.50 million for the quarter, compared to analyst estimates of $13.31 million. As a group, analysts predict that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Insider Transactions at Personalis

In other news, CEO Christopher M. Hall sold 29,612 shares of Personalis stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the transaction, the chief executive officer owned 148,486 shares in the company, valued at $1,334,889.14. The trade was a 16.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at approximately $1,772,857.24. The trade was a 38.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 134,481 shares of company stock worth $1,397,564. 3.80% of the stock is currently owned by insiders.

Personalis Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.